Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing

The spectrum of neurodegenerative diseases known today is quite extensive. The complexities of their research and treatment lie not only in their diversity. Even many years of struggle and narrowly focused research on common pathologies such as Alzheimer’s, Parkinson’s, and other brain diseases have...

Full description

Bibliographic Details
Main Authors: Vladlena S. Makeeva, Nadezhda S. Dyrkheeva, Olga I. Lavrik, Suren M. Zakian, Anastasia A. Malakhova
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/24/23/16798
Description
Summary:The spectrum of neurodegenerative diseases known today is quite extensive. The complexities of their research and treatment lie not only in their diversity. Even many years of struggle and narrowly focused research on common pathologies such as Alzheimer’s, Parkinson’s, and other brain diseases have not brought cures for these illnesses. What can be said about orphan diseases? In particular, Huntington’s disease (HD), despite affecting a smaller part of the human population, still attracts many researchers. This disorder is known to result from a mutation in the <i>HTT</i> gene, but having this information still does not simplify the task of drug development and studying the mechanisms of disease progression. Nonetheless, the data accumulated over the years and their analysis provide a good basis for further research. Here, we review studies devoted to understanding the mechanisms of HD. We analyze genes and molecular pathways involved in HD pathogenesis to describe the action of repurposed drugs and try to find new therapeutic targets.
ISSN:1661-6596
1422-0067